Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 9
Submit an article Journal homepage
439
Views
3
CrossRef citations to date
0
Altmetric
Commentary

Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?

Rory M. ShallisDepartment of Internal Medicine School of Medicine, Yale University, New Haven, USA;
&
Amer M. ZeidanDepartment of Internal Medicine School of Medicine, Yale University, New Haven, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, USACorrespondence[email protected]
Pages 2015-2017 | Received 08 Jan 2018, Accepted 15 Jan 2018, Published online: 07 Feb 2018
Supplemental material

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.2 MB)

Table 1. Selected prospective studies of lenalidomide efficacy and toxicity in non-del(5q) LR-MDS after ESA failure or ineligibility

Download MS Word (19.1 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.